作者
Oliver W Press, Janet F Eary, Christopher C Badger, Paul J Martin, Frederick R Appelbaum, Ron Levy, Richard Miller, S Brown, WB Nelp, KA Krohn
发表日期
1989/8
期刊
Journal of clinical oncology
卷号
7
期号
8
页码范围
1027-1038
简介
The biodistribution, toxicity, and therapeutic potential of anti-CD37 monoclonal antibody (MoAb) MB-1 labeled with iodine 131 (131I) was evaluated in ten patients with advanced-, low- or intermediate-grade non-Hodgkin's lymphomas who failed conventional treatment. Sequential dosimetric studies were performed with escalating amounts of antibody MB-1 (0.5, 2.5, 10 mg/kg) trace-labeled with 5 to 10 mCi 131I. Serial tumor biopsies and gamma camera imaging showed that the 10 mg/kg MoAb dose yielded the best MoAb biodistribution in the ten patients studied. Biodistribution studies in the five patients with splenomegaly and tumor burdens greater than 1 kg indicated that not all tumor sites would receive more radiation than normal organs, and these patients were therefore not treated with high-dose radioimmunotherapy. The other five patients did not have splenomegaly and had tumor burdens less than 0.5 kg …
引用总数
学术搜索中的文章
OW Press, JF Eary, CC Badger, PJ Martin… - Journal of clinical oncology, 1989